Blurbs

Analysts Have Conflicting Sentiments on These Healthcare Companies: Amarin (AMRN), Arrowhead Pharmaceuticals (ARWR) and RegenXBio (RGNX)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Amarin (AMRNResearch Report), Arrowhead Pharmaceuticals (ARWRResearch Report) and RegenXBio (RGNXResearch Report).

Amarin (AMRN)

In a report released today, Paul Choi from Goldman Sachs maintained a Sell rating on Amarin, with a price target of $1.50. The company’s shares closed last Monday at $1.41, close to its 52-week low of $1.11.

According to TipRanks.com, Choi is a 4-star analyst with an average return of 7.8% and a 50.5% success rate. Choi covers the Healthcare sector, focusing on stocks such as Silverback Therapeutics, BridgeBio Pharma, and Urogen Pharma.

Currently, the analyst consensus on Amarin is a Moderate Buy with an average price target of $6.75.

See the top stocks recommended by analysts >>

Arrowhead Pharmaceuticals (ARWR)

Goldman Sachs analyst Madhu Kumar maintained a Buy rating on Arrowhead Pharmaceuticals today and set a price target of $66.00. The company’s shares closed last Monday at $36.05, close to its 52-week low of $27.87.

According to TipRanks.com, Kumar is a 5-star analyst with an average return of 17.3% and a 48.1% success rate. Kumar covers the Healthcare sector, focusing on stocks such as Cerevel Therapeutics Holdings, Iovance Biotherapeutics, and Arvinas Holding Company.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Arrowhead Pharmaceuticals with a $73.14 average price target, representing a 100.7% upside. In a report issued on May 11, Robert W. Baird also upgraded the stock to Buy with a $60.00 price target.

RegenXBio (RGNX)

Morgan Stanley analyst Vikram Purohit maintained a Buy rating on RegenXBio today and set a price target of $47.00. The company’s shares closed last Monday at $19.56, close to its 52-week low of $18.69.

According to TipRanks.com, Purohit has 0 stars on 0-5 stars ranking scale with an average return of -25.3% and a 18.9% success rate. Purohit covers the Healthcare sector, focusing on stocks such as Arcutis Biotherapeutics, Theravance Biopharma, and Talaris Therapeutics.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for RegenXBio with a $47.67 average price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on AMRN:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More
Videos